Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: A population-based study

Arthritis and Rheumatism

Volumn 64, Issue 8, 2012, Pages 2792-2802

  Valkhoff, Vera E ^a   Van Soest, Eva M ^a   Mazzaglia, Giampiero ^b   Molokhia, Mariam ^c   Schade, René ^a   Trifiro, Gianluca ^a,f   Goldstein, Jay L ^d   Hernandez Diaz, Sonia ^e   Kuipers, Ernst J ^a   Sturkenboom, Miriam C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Health Search   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; ROFECOXIB;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH PROTECTION; STOMACH ULCER; TREATMENT DURATION; UNITED KINGDOM; UPPER GASTROINTESTINAL BLEEDING;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GREAT BRITAIN; HUMANS; INCIDENCE; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT COMPLIANCE; PROTON PUMP INHIBITORS; REGISTRIES; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS; STOMACH ULCER; UPPER GASTROINTESTINAL TRACT;

EID: 84864115219     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34433     Document Type: Article

References (21)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
2. Rostom A, Muir K, Dube C, Jolicoeur E, Boucher M, Joyce J, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-28, 828.e1-5.
3. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
4. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-55.
5. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.
6. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9.
7. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621-6.
8. Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 2007; 133: 790-8.
9. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-10.
10. Targownik LE, Metge CJ, Leung S, Chateau DG,. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008; 134: 937-44.
11. NSAIDs-prescribing issues. In: NHS Clinical Knowledge Summaries safe practical clinical answers; 2009. URL:.
12. Lanza FL, Chan FK, Quigley EM,. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
13. Van Soest EM, Valkhoff VE, Mazzaglia G, Schade R, Molokhia M, Goldstein JL, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011; 60: 1650-9.
14. World Health Organization. Classification of diseases. URL:.
15. Lamberts H, Wood M, Hofmans-Okkes IM,. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992; 9: 330-9.
16. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. URL:.
17. Cricelli C, Mazzaglia G, Samani F, Marchi M, Sabatini A, Nardi R, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003; 25: 254-7.
18. Hernandez-Diaz S, Rodriguez LA,. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9.
19. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J,. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.
20. Goldstein JL, Howard KB, Walton SM, McLaughlin TP, Kruzikas DT,. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006; 4: 1337-45.
21. Moride Y, Abenhaim L,. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-7.